A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


September 14, 2010

People With X4 Virus Who Failed Selzentry Have Good Long-Term Results

People who failed treatment on the entry inhibitor Selzentry had good long-term health outcomes after switching their antiretroviral (ARV) regimen, despite having an HIV-strain that has been associated with poorer health. These data were presented September 13 at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

Most strains of HIV use a cellular coreceptor known as CCR5 or “R5” to enter and infect CD4 cells. Other strains use a different receptor, CXCR4 or “X4,” while still other strains use both. A number of years ago, scientists observed that the dominant strain of HIV switches from R5 to X4 in people with advanced disease and that people with X4 or mixed virus have lower CD4 cells and more accelerated disease progression than people with only R5 virus..

This phenomenon was a serious concern as the first CCR5 entry inhibitor, Selzentry (maraviroc), was being developed. If Selzentry—by suppressing R5 virus—caused X4 virus to develop or dominate, scientists worried it could lead to much faster disease progression.

To help address this concern, researchers from Pfizer—Selzentry’s maker—analyzed follow-up data from 15 people who had experienced treatment failure while taking Selzentry in the MERIT study. MERIT was designed to compare Selzentry with Sustiva (efavirenz) in people starting ARV therapy for the first time. To be eligible for this analysis, a person needed to have a switch in his or her virus’s coreceptor preference, or “tropism,” after starting treatment.

The average CD4 count of these study participants before staring Selzentry was 220, and the average viral load was 117,000. The average time from starting treatment and having a tropism switch was 85 days, though the average time to treatment failure was 183 days. Average follow-up of the participants after failing on Selzentry was nearly four years. In two of the 15 people, the shift from R5 to X4 virus persisted even after they stopped taking Selzentry.

Unfortunately, only one test was available to measure the tropism of a person’s virus at the time that MERIT was running, and this test wasn’t very sensitive. This meant that a substantial percentage of people initially classified as having only R5 virus and let into the study actually had low levels of X4 virus as well. Based on reanalysis of the 15 study participants using more sensitive tests that are now available, as many as eight actually had measurable X4 virus during the screening period, and would have been excluded from the study.

Regardless, most of the participants had no negative consequences from their viral tropism switch. Fourteen of the 15 achieved undetectable virus on their subsequent regimen. Also, there were only two serious health problems during the follow-up—secondary syphilis and tuberculosis—and experts determined that neither had any relationship to its ARV therapy.

“With extended follow-up, no adverse clinical consequences were observed following failure-associated emergence of CXCR4-using virus with [Selzentry],” concluded the authors. “Subjects had good immunological outcomes and responded to subsequent therapy.”

Search: Selzentry, maraviroc, Pfizer, entry inhibitor, CCR5, R5, CXCR4, X4, tropism, dual, mixed

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.